Literature DB >> 21480229

Revisiting cancer immunoediting by understanding cancer immune complexity.

Masoud H Manjili1.   

Abstract

Since 1909, the cancer immunosurveillance concept has undergone four distinct eras. These include a general acceptance during 1957–1974, an abandonment during 1974–1996, resurrection during 1996–2001 in the form of an elegant theory of tumour immunoediting proposed by Robert Schreiber, and a retreat since 2006. Recently, in the Journal of Pathology, Ciampricotti et al reported an elegant experimental model designed by establishing RAG2−/−/MMTV-NeuT mice. Using this, they demonstrated that the development and metastasis of HER-2/neu-positive spontaneous mammary carcinoma were not altered by the presence or absence of the adaptive immune system. Their fascinating results are a call to revisit controversial reports as to an effective role of the adaptive immune system in tumour inhibition versus tumour promotion or tolerance in the development of spontaneous carcinomas. Ciampricotti and colleagues present a strong case for revising our ideas of cancer immunoediting and appreciating the complexity of the interaction between cancer and the immune system.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21480229      PMCID: PMC3092128          DOI: 10.1002/path.2865

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  42 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 2.  Occurrence of malignancy in immunodeficiency diseases. A literature review.

Authors:  R A Gatti; R A Good
Journal:  Cancer       Date:  1971-07       Impact factor: 6.860

Review 3.  Tumor antigens.

Authors:  G Klein
Journal:  Annu Rev Microbiol       Date:  1966       Impact factor: 15.500

4.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

5.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 6.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

7.  Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.

Authors:  I Caroline Le Poole; Adam I Riker; M Eugenia Quevedo; Lawrence S Stennett; Ena Wang; Francesco M Marincola; W Martin Kast; June K Robinson; Brian J Nickoloff
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 8.  Sarcomas in organ allograft recipients.

Authors:  I Penn
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

Review 9.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

10.  Decreased tumor surveillance in perforin-deficient mice.

Authors:  M E van den Broek; D Kägi; F Ossendorp; R Toes; S Vamvakas; W K Lutz; C J Melief; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  8 in total

Review 1.  The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells.

Authors:  Bong Ihn Koh; Yibin Kang
Journal:  EMBO Rep       Date:  2012-05       Impact factor: 8.807

Review 2.  An immunologic portrait of cancer.

Authors:  Maria Libera Ascierto; Valeria De Giorgi; Qiuzhen Liu; Davide Bedognetti; Tara L Spivey; Daniela Murtas; Lorenzo Uccellini; Ben D Ayotte; David F Stroncek; Lotfi Chouchane; Masoud H Manjili; Ena Wang; Francesco M Marincola
Journal:  J Transl Med       Date:  2011-08-29       Impact factor: 5.531

Review 3.  Tumor immunotherapy: lessons from autoimmunity.

Authors:  Christian Maueröder; Luis Enrique Munoz; Ricardo Alfredo Chaurio; Martin Herrmann; Georg Schett; Christian Berens
Journal:  Front Immunol       Date:  2014-05-13       Impact factor: 7.561

Review 4.  Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses.

Authors:  Alexandre Morrot; Leonardo Marques da Fonseca; Eduardo J Salustiano; Luciana Boffoni Gentile; Luciana Conde; Alessandra Almeida Filardy; Tatiany Nunes Franklim; Kelli Monteiro da Costa; Celio Geraldo Freire-de-Lima; Leonardo Freire-de-Lima
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

5.  Have Cells Harboring the HIV Reservoir Been Immunoedited?

Authors:  Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

6.  DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.

Authors:  Jiajia Hu; Zhengting Wang; Zhengxi Chen; Ao Li; Jing Sun; Minhua Zheng; Jibo Wu; Tianli Shen; Ju Qiao; Lin Li; Biao Li; Dianqing Wu; Qian Xiao
Journal:  Biomed Pharmacother       Date:  2020-05-20       Impact factor: 6.529

Review 7.  Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity.

Authors:  Malgorzata Wachowska; Angelika Muchowicz; Jakub Golab
Journal:  Front Oncol       Date:  2015-07-30       Impact factor: 6.244

8.  Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer.

Authors:  Christina Kober; Stephanie Weibel; Susanne Rohn; Lorenz Kirscher; Aladar A Szalay
Journal:  Mol Ther Oncolytics       Date:  2015-06-24       Impact factor: 7.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.